STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and more
Stat News • 5/8/2026
Summary
The FDA has proposed removing references to "gender" from its regulations, which has raised concerns about potential unintended consequences on research. Additionally, the FDA is implementing a program for one-day inspections.
Advertisement
Lindy Score Breakdown (V4.2)
5d
Age
1
Sources
from cluster
126
Hours Since Seen
Final Score2/100
CategoryAntiLindy
StatusActive
Recency Multiplier16% (0.5^126/48)
Hero EligibleYes
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 5 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Related Stories
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
Stat News • Today
STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
Stat News • 2 days ago
STAT+: STAT examines America’s deadliest drug
Stat News • 1 day ago
STAT+: Drug meant to make gene therapy safer may also make it less effective
Stat News • Today
STAT+: Hims’ sales miss as telehealth competition grows
Stat News • 1 day ago
STAT+: In the battle of sepsis algorithms, performance alone doesn’t predict victory
Stat News • 1 day ago
STAT+: Why Marty Makary was the worst FDA commissioner in 25 years
Stat News • 1 day ago
STAT+: AI medical devices’ dirty FDA secret
Stat News • Today
STAT+: Scientists link boy’s tumor to gene therapy viruses, in rare finding
Stat News • Today
STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
Stat News • 1 day ago
